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from published studies conducted in the UK and included
direct medical and indirect costs. Resource unit costs
were obtained from published sources. Vaccination pro-
gram costs were included. Future costs were discounted
5%. RESULTS: The incremental cost per year of life
gained in the under one year old group was £4,280 with-
out discounting the benefit and £6,357 with discounting.
The incremental cost per life year gained in the cohort
aged 1–4 years was £1,060 without discounting the bene-
fit and £1,557 with discounting the years of life gained.
Both age group ratios increase as the costs of managing
acute and long-term sequelae are decreased. Assuming a
higher proportion of meningococcal infections are sero-
type C (40%) results in ratios of £3,146 and £470 for the
younger and older groups, respectively. CONCLU-
SIONS: The cost-effectiveness ratios for vaccinating chil-
dren under age 1 and between ages 1 and 4 fall within the
generally acceptable range of costs for adopting new
technology.
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Cost-effectiveness of secondary prevention of CHD in the
Western World with simvastatin (S) is well established.
OBJECTIVE: Cost-effective evaluation of secondary pre-
vention of CHD with simvastatin in the Polish setting
with the health care system in a transition period.
METHOD: It was assumed that the effects of S in Polish
patients would be the same as those of Scandinavian Sim-
vastatin Survival Study. Direct medical costs were ob-
tained from Polish sources. ICER was calculated dividing
net costs by years of life gained during 5.4 years of treat-
ment with S projected over an average life expectancy of
10 years. One-way and multi-way sensitivity analyses
were performed. Frequency of hospitalizations, costs of
hospitalizations, and life-years saved were the variables
used in Monte Carlo analysis. RESULTS: Net cost/pa-
tient (discounted at 5%) was $2478.5; cost per life-years
saved (LYS) was $10,326.8 (mean ICER from Monte
Carlo analysis was $10,243.9). ICER value was highly
sensitive to the price of S and relatively insensitive to the
value of savings (including saving of PTCA, CABG, myo-
cardial infarction, and hospitalisations). The latter, in
Polish settings, amounted to only 8.2% of drug cost (in
Sweden 30%). The cost per LYS is higher than the cost
of 1 year of hemodialysis and about 3 times higher than
the GNP per capita ($3527.6) in Poland. CONCLU-
SIONS: Results indicate that secondary prevention of
CHD in patients with mild hypercholesterolemia with S
in Poland is hardly cost-effective due to the low value of
savings. The value of medical services in Poland is proba-
bly underestimated.
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OBJECTIVES: Cost-effectiveness estimation of treatment
with a fixed-dose combination of diclofenac and miso-
prostol (FDC D-M) 50 mg/200 mcg bid compared with
diclofenac (D) 50 mg bid in prevention of NSAID-induced
ulcers in rheumatoid arthritis (RA) patients in Poland.
METHODS: A decision model for FDC D-M in the Pol-
ish health care context was developed, based on epidemi-
ological and clinical data from the literature and local
data on health care resource utilization and unit cost.
Only direct medical costs are analyzed. The perspective
of health care payers (sickness funds  patients) is taken.
The time horizon is 3 months, but consequences of a
longer time horizon are discussed. Cost-effectiveness was
calculated for the treatment of all RA patients and risk
groups only. Effectiveness was expressed in life-years
saved. The cost-effectiveness threshold, calculated on basis
of 1-year of haemodialysis treatment cost ($15,600 US)
or national GDP per head at PPP ($6300 US), was sug-
gested to asses whether the FDC D-M therapy should be
adopted. RESULTS: Analysis showed that FDC D-M treat-
ment in RA patients gives additional life years for extra
cost. In all RA patients (aged 65) 1 LYG costs $33,700
US. Cost per LYG was below the suggested cost-effective-
ness threshold only in patients at high risk (history of
peptic ulcer disease or GI bleeding, disability—mHAQ
1.5, concomitant antacid therapy). One-way sensitivity
analysis showed that outcomes are sensitive to changes
in: price differences between FDC-D-M and D, percent
ulcers, and the efficacy of misoprostol. CONCLUSION:
FDC D-M treatment in Poland is cost-effective only in
RA patients at high risk for NSAID-induced ulcers.
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Cisapride, an oral GI prokinetic agent, was reported to
cause serious cardiac arrhythmia in patients who received
imidazole antifungals, macrolide antibiotics, or protease
inhibitors. Several label changes and dear Dr. letters were
sent to prescribers in February and October 1995, and
June 1998. OBJECTIVE: To quantify the effectiveness of
label changes and dear Dr. letters on patient medication
